公开(公告)号：GR3030354T3

公开(公告)日：1999-09-30

申请号：GR990401443

申请日：1999-05-27

Applicant: ABBOTT LAB

Inventor： BASHA ANWER ,  BHATIA PRAMILA ,  BROOKS DEE W ,  CRAIG RICHARD A ,  RATAJCZYK JAMES D ,  STEWART ANDREW O

IPC: A61K31/17 ,  A61K31/38 ,  A61K31/381 ,  A61K31/425 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4433 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00 ,  A61P17/00 ,  A61P25/00 ,  A61P27/16 ,  A61P29/00 ,  A61P37/08 ,  A61P43/00 ,  C07C273/18 ,  C07C275/24 ,  C07C275/64 ,  C07D213/61 ,  C07D277/28 ,  C07D307/52 ,  C07D333/20 ,  C07D333/22 ,  C07D405/06 ,  C07D409/04 ,  C07D409/06 ,  C07D417/04 ,  C07C275/20

Abstract: PCT No. PCT/US93/10675 Sec. 371 Date Apr. 13, 1995 Sec. 102(e) Date Apr. 13, 1995 PCT Filed Nov. 5, 1993 PCT Pub. No. WO94/11342 PCT Pub. Date May 26, 1994The invention relates to compounds having activity to inhibit lipoxygenase enzyme activity, to pharmaceutical compositions comprising these compounds, and to a medical method of treating. More particularly, this invention concerns certain substituted arylalkynyl- and ((heteroaryl)alkynyl)-N-hydroxy-ureas which inhibit leukotriene biosynthesis, to pharmaceutical compositions of these compounds and to a method of inhibiting leukotriene biosynthesis.

公开(公告)号：AT178049T

公开(公告)日：1999-04-15

申请号：AT94902209

申请日：1993-11-05

Applicant: ABBOTT LAB

Inventor： BASHA ANWER ,  BHATIA PRAMILA ,  BROOKS DEE W ,  CRAIG RICHARD A ,  RATAJCZYK JAMES D ,  STEWART ANDREW O

IPC: A61K31/17 ,  A61K31/38 ,  A61K31/381 ,  A61K31/425 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4433 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00 ,  A61P17/00 ,  A61P25/00 ,  A61P27/16 ,  A61P29/00 ,  A61P37/08 ,  A61P43/00 ,  C07C273/18 ,  C07C275/24 ,  C07C275/64 ,  C07D213/61 ,  C07D277/28 ,  C07D307/52 ,  C07D333/20 ,  C07D333/22 ,  C07D405/06 ,  C07D409/04 ,  C07D409/06 ,  C07D417/04 ,  C07C275/20

Abstract: PCT No. PCT/US93/10675 Sec. 371 Date Apr. 13, 1995 Sec. 102(e) Date Apr. 13, 1995 PCT Filed Nov. 5, 1993 PCT Pub. No. WO94/11342 PCT Pub. Date May 26, 1994The invention relates to compounds having activity to inhibit lipoxygenase enzyme activity, to pharmaceutical compositions comprising these compounds, and to a medical method of treating. More particularly, this invention concerns certain substituted arylalkynyl- and ((heteroaryl)alkynyl)-N-hydroxy-ureas which inhibit leukotriene biosynthesis, to pharmaceutical compositions of these compounds and to a method of inhibiting leukotriene biosynthesis.

公开(公告)号：CA2136077A1

公开(公告)日：1994-05-26

申请号：CA2136077

申请日：1993-11-05

Applicant: ABBOTT LAB

Inventor： BASHA ANWER ,  BHATIA PRAMILA ,  BROOKS DEE W ,  CRAIG RICHARD A ,  RATAJCZYK JAMES D ,  STEWART ANDREW O

IPC: A61K31/17 ,  A61K31/38 ,  A61K31/381 ,  A61K31/425 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4433 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00 ,  A61P17/00 ,  A61P25/00 ,  A61P27/16 ,  A61P29/00 ,  A61P37/08 ,  A61P43/00 ,  C07C273/18 ,  C07C275/24 ,  C07C275/64 ,  C07D213/61 ,  C07D277/28 ,  C07D307/52 ,  C07D333/20 ,  C07D333/22 ,  C07D405/06 ,  C07D409/04 ,  C07D409/06 ,  C07D417/04 ,  C07D333/24 ,  C07D413/06 ,  C07D417/06 ,  C07D277/30 ,  C07D263/32 ,  A61K31/33 ,  C07D307/54 ,  C07D333/60

Abstract: 2136077 9411342 PCTABS00032 The invention relates to compounds having activity to inhibit lipoxygenase enzyme activity, to pharmaceutical compositions comprising these compounds, and to a medical method of treating. More particularly, this invention concerns certain substituted arylalkynyl- and ((heteroaryl)alkynyl)-N-hydroxy-ureas which inhibit leukotriene biosynthesis, to pharmaceutical compositions of these compounds and to a method of inhibiting leukotriene biosynthesis.

公开(公告)号：CA2117381A1

公开(公告)日：1993-09-02

申请号：CA2117381

申请日：1993-02-08

Applicant: ABBOTT LAB

Inventor： BROOKS DEE W ,  STEWART ANDREW O ,  BHATIA PRAMILY ,  CRAIG RICHARD A

IPC: A61K31/34 ,  A61K31/341 ,  A61P43/00 ,  C07D307/58 ,  C07D307/64 ,  C07D405/12 ,  C07D307/56 ,  C07F7/10 ,  A61K31/44 ,  A61K31/47 ,  A61K31/695

Abstract: (SEE FIGURE I) Compounds useful in inhibiting the biosynthesis of leukotrienes have structure ( I), where M is hydrogen, a pharmaceutically acceptable cation, or a metabolically cleavable group, R4 is alkyl, cycloalkyl o r -NR5R6, where R5 and R5 are hydrogen, alkyl cycloalkyl or alkanoyl, where A is a valence bond or is a straight or branched d ivalent alkylene group of from one to twelve carbon atoms, R2 and R3 are independently selected from hydrogen, straigh t or branched alkyl of from one to twelve carbon atoms, halogen, or trifluoroalkyl, and R1 is selected from phenoxy, pheny lthio, 2-, 3-, or 4-pyridyloxy, 1-, or 2naph-thyloxy, or 2-, 4-, 5-, or 8-quinolytoxy all optionally substituted with al kyl, haloalkyl, alkoxy, hydroxy or halogen.

公开(公告)号：MX9300994A

公开(公告)日：1993-09-01

申请号：MX9300994

申请日：1993-02-24

Applicant: ABBOTT LAB

Inventor： BROOKS DEE W ,  STEWART ANDREW O ,  BHATIA PRAMILA ,  CRAIG RICHARD A

IPC: A61K31/34 ,  A61K31/341 ,  A61P43/00 ,  C07D307/58 ,  C07D307/64 ,  C07D405/12 ,  C07C275/00

Abstract: Compounds useful in inhibiting the biosynthesis of leukotrienes have the structure where M is hydrogen, a pharmaceutically acceptable cation, or a metabolically cleavable group, R4 is alkyl, cycloalkyl or -NR5R6, where R5 and R6 are hydrogen, alkyl, cycloalkyl or alkanoyl, where A is a valence bond or is a straight or branched divalent alkylene group of from one to twelve carbon atoms, R2 and R3 are independently selected from hydrogen, straight or branched alkyl of from one to twelve carbon atoms, halogen, or trifluoroalkyl, and R1 is selected from phenoxy, phenylthio, 2-, 3-, or 4-pyridyloxy, 1 or 2-naphthyloxy, or 2,4,5, or 8-quinolyloxy, all optionally substituted with alkyl, haloalkyl, alkoxy, hydroxy or halogen.